Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients Transitioned from Parenteral or Inhaled Prostacyclins: Case Series and Treatment Protocol-Reference-Cited by-同舟云学术

Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients Transitioned from Parenteral or Inhaled Prostacyclins: Case Series and Treatment Protocol

Published:2016-03 Issue:1 Volume:6 Page:132-135
ISSN:2045-8940
Container-title:Pulmonary Circulation
language:en
Short-container-title:Pulm. circ.

Author:

Coons James C.¹²,Miller Taylor²,Simon Marc A.³⁴,Ishizawar David C.⁴⁵,Mathier Michael A.⁴⁵

Affiliation:

1. University of Pittsburgh School of PharmacyPittsburghPennsylvaniaUSA

2. University of Pittsburgh Medical Center (UPMC)PittsburghPennsylvaniaUSA

3. Vascular Medicine InstituteUniversity of Pittsburgh School of MedicinePittsburghPennsylvaniaUSA

4. Heart and Vascular InstituteUPMCPittsburghPennsylvaniaUSA

5. University of Pittsburgh School of MedicinePittsburghPennsylvaniaUSA

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1086/685111

Reference6 articles.

1. Updated treatment algorithm of pulmonary arterial hypertension;Galiè N;J Am Coll Cardiol,2013

2. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial;Jing ZC;Circulation,2013

3. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type‐5 inhibitor therapy (the FREEDOM‐C study): a randomized controlled trial;Tapson VF;Chest,2012

4. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type‐5 inhibitor therapy (the FREEDOM‐C2 study): a randomized control trial;Tapson VF;Chest,2013

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-Term Experience and Safety of Transitioning from Subcutaneous Treprostinil to Oral Selexipag in the High-Risk Pulmonary Hypertension Patient: A Case Report;ACTA CARDIOL SIN;2023

2. Transition from IV epoprostenol to oral treprostinil in a patient with group 1 pulmonary arterial hypertension;American Journal of Health-System Pharmacy;2021-06-08

3. Effects of treprostinil on pulmonary arterial hypertension during surgery for congenital heart disease complicated with severe pulmonary arterial hypertension;Minerva Cardiology and Angiology;2021-04

4. An expert panel delphi consensus statement on patient selection and management for transitioning between oral and inhaled treprostinil;Pulmonary Pharmacology & Therapeutics;2021-02

5. A multicenter retrospective study of patients with pulmonary hypertension transitioned from inhaled to oral treprostinil;Pulmonary Circulation;2021-01